Anavex Life Sciences Corp (AVXL)

[Rubyred77]

Frontotemporal degeneration (FTD) -- the most common dementia for people under age 60 -- inflicts a significantly higher economic burden on both patients and their caregivers, a new study shows. While the social and economic cost of Alzheimer's is well documented, the study found that the average annual costs associated with FTD to total $119,654, nearly two times the reported annual cost of Alzheimer's.source

Right behind a-273, is a-371, which we cant forget the pr released april 8, 2016 reading:
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia

FULL PR

So much upside potential from here. I sure hope Missling wouldn't sell out for a measly $2-$5B